Author

T. Zimmerman

Institution: BeiGene (China)

Observed institution: BeiGene (China)

OpenAlex ID: A5089322820

P965: Follow-up Analysis of the Randomized Phase Ii Trial of Bortezomib, Lenalidomide, Dexamthasone With/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (swog-1211)

2022 · S. Usmani, A. Hoering, et al. · HemaSphere

Works count: 1

Citation count:

H-index:

I10-index: